MAPT and Alzheimer disease: The results indicated that TREM2/DAP12 might mediate the down-regulation of TLR4/MyD88, NLRP3/Caspase1 signaling pathways, the AD signature protein of IBA-1/Tau, the inflammatory protein expression of iNOS/COX2, and the release of inflammatory factors TNF-α, IL-6, and IL-1β.